Going nuclear: Improved antisense oligonucleotide activity through conjugation with a nuclear importer

04 December 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Antisense oligonucleotides (ASOs) are a promising class of therapeutics designed to modulate gene expression. Both key mechanisms of action for ASOs operate in the nucleus: splice-switching ASOs modify pre-mRNA, processed in the nucleus, and mRNA-degrading ASOs require RNase H, an enzyme predominantly active in the nucleus. Therefore, to achieve maximal efficacy, ASOs require efficient nuclear delivery. Current ASO therapeutics shuttle in and out of the nucleus inefficiently. In this work, we have synthesised ASO conjugates for active nuclear import, by covalent conjugation with a potent small-molecule nuclear importer, (+)-JQ1. (+)-JQ1 is a well-characterised high-affinity binder for members of the BET bromodomain family of proteins and was recently shown to transport cytoplasmic proteins into the nucleus. Our (+)-JQ1-ASO conjugates outperformed their unmodified counterparts for both splice-switching and mRNA knockdown in the nucleus, at all concentrations tested. In particular, we improved the performance of Oblimersen, a BCL-2 ASO drug that failed phase-III clinical trials, showing that this therapeutic may merit re-evaluation. This work shows that the covalent modification of ASOs with a small-molecule nuclear importer can significantly improve target engagement and pave the way for more effective therapeutics.

Keywords

Antisense Oligonucleotides
ASOs
Nucleic acid therapeutics
Nuclear import

Supplementary materials

Title
Description
Actions
Title
Supplementary Information
Description
Supplementary Information
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.